As shown in figure 7A, B, HER2-DC1 i.t. combined with trastuzumab and pertuzumab treatment showed a more remarkable antitumor response with tumor regression in 65% of treated mice and prolonged survival. This evidence concerns the gene ERBB2 and neoplasm.